US2022016224A1PendingUtilityA1

Methods and compositions for treating aging-associated conditions

65
Assignee: UNIV LELAND STANFORD JUNIORPriority: Jun 15, 2015Filed: Oct 8, 2021Published: Jan 20, 2022
Est. expiryJun 15, 2035(~8.9 yrs left)· nominal 20-yr term from priority
Inventors:Anton Wyss-CorayJoseph M. Castellano
A61P 43/00A61P 25/28A61K 38/57A61P 39/00A61K 45/00A61K 38/55A61P 25/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating an adult mammal for an aging-associated condition are provided. Aspects of the methods include enhancing a TIMP activity, e.g., a TIMP2 activity, in the mammal in a manner sufficient to treat the adult mammal for the aging-associated condition. Also provided are compositions for use in practicing methods of the invention. A variety of aging-associated conditions may be treated by practice of the methods, which conditions include cognitive impairments.

Claims

exact text as granted — not AI-modified
1 . A method of treating an adult mammal for an aging-associated condition, the method comprising:
 enhancing a TIMP activity in the mammal in a manner sufficient to treat the adult mammal for the aging-associated condition.   
     
     
         2 . The method according to  claim 1 , wherein the TIMP activity is a TIMP1, TIMP2, TIMP3 or TIMP4 activity. 
     
     
         3 . The method according to  claim 2 , wherein the TIMP activity is a TIMP2 activity. 
     
     
         4 . The method according to  claim 1 , where the method comprises enhancing a systemic TIMP activity. 
     
     
         5 . The method according to  claim 1 , wherein the method comprises increasing a systemic level of a TIMP active agent in the mammal. 
     
     
         6 . The method according to  claim 5 , wherein the systemic level of a TIMP active agent is increased by administering a TIMP active agent to the mammal. 
     
     
         7 . The method according to  claim 6 , wherein the TIMP active agent is a TIMP polypeptide or mimetic thereof. 
     
     
         8 . The method according to  claim 7 , wherein the TIMP active agent is a TIMP polypeptide. 
     
     
         9 . The method according to  claim 8 , wherein the TIMP polypeptide has a sequence that is at least 60% identical to any of SEQ ID NOS: 1 to 4. 
     
     
         10 . The method according to  claim 1 , wherein the method comprises enhancing expression of an endogenous TIMP coding sequence. 
     
     
         11 . The method according to  claim 1 , wherein the mammal is a primate. 
     
     
         12 . The method according to  claim 1 , wherein the adult mammal is an elderly mammal. 
     
     
         13 . The method according to  claim 11 , wherein the primate is a human. 
     
     
         14 . The method according to  claim 1 , wherein the aging-associated condition comprises a cognitive impairment or a cognitive decline disease condition 
     
     
         15 . The method according to  claim 1 , wherein the adult mammal suffers from an aging associated disease condition. 
     
     
         16 . The method according to  claim 6 , wherein the TIMP active agent comprises a nucleic acid. 
     
     
         17 . The method according to  claim 6 , wherein the TIMP active agent comprises a modified TIMP polypeptide. 
     
     
         18 . The method according to  claim 6 , wherein the TIMP active agent comprises a pegylated TIMP polypeptide. 
     
     
         19 . The method according to  claim 6 , wherein the TIMP active agent comprises an TIMP polypeptide fused to an antibody or portion thereof. 
     
     
         20 . The method according to  claim 19 , wherein the antibody is an IgG antibody.

Join the waitlist — get patent alerts

Track US2022016224A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.